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Background
Trial interim analyses are traditionally based on an
assessment of efficacy and safety. Early evaluation of
cost-effectiveness and a quantification of the societal
value of further research could provide additional infor-
mation to inform stop-go decisions.
Objective
To assess the potential utility of early cost-effectiveness
analysis (CEA) and value of information analysis (VOIA)
within the context of a randomised clinical trial.
Methods
The ARCTIC trial randomised patients with previously
untreated Chronic Lymphocytic Leukaemia to receive
fludarabine, cyclophosphamide, mitoxantrone and low
dose rituximab (FCM-miniR) or fludarabine, cyclopho-
sphamide and rituximab (FCR; standard care). An
interim efficacy analysis was conducted after 103
patients had completed therapy. CEA and VOIA were
conducted using a Markov decision model, based on
subsequent data from 200 patients.
Results
The trial was terminated early based on the results of the
interim efficacy analysis. FCM-MiniR was not expected
to be cost-effective over a lifetime horizon, producing an
average lifetime cost saving of £7,708 and health loss of
-0.67 QALYs. The VOIA, however, suggested a high
value of further research due to uncertainty around key
parameters. Whilst the CEA results support the interim
efficacy findings, the VOIA results highlight the cost of
trial termination in terms of potential population net
health loss (1,050 QALYs) by foregoing the opportunity
to collect additional data.
Conclusion
Early evaluation of cost-effectiveness within clinical trials
could provide useful information in addition to efficacy
data for interim analyses. Future research proposals
should incorporate CEA and VOIA at interim analysis,
allowing research-value to influence stop-go decisions.
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